Skip to main content
Grafa
Health
Tvardi Q2 net loss reaches $6.5m
Image for illustrative purposes only. Not a real photo.

Tvardi Q2 net loss reaches $6.5m

Share
  • Tvardi Therapeutics reported a Q2 2026 net loss of $6.5 million, while R&D expenses declined to $4 million.
  • TVRD shares were up about 6.2% at $1.88 in Friday trading following the results.
  • Tvardi selected ulcerative colitis as TTI-109’s first indication and plans a clinical trial in 2027, subject to IND clearance and additional funding.

Tvardi Therapeutics (NASDAQ:TVRD) reported a Q2 2026 net loss of $6.5 million as R&D spending declined to $4 million.

The result compared with $4.2 million of net income a year earlier, which included a $12.7 million non-cash convertible-note valuation gain.

Tvardi held $15.8 million in cash and investments and expects that balance to fund current operations through its HCC readout into Q3 2027.

Following the announcement, Tvardi Therapeutics' share price was up about 6.2% at $1.88 in Friday trading.

Tvardi selected ulcerative colitis as TTI-109’s initial indication after Phase 1 data showed pharmacodynamic evidence of STAT3 target engagement and improved tolerability.

The company expects TTI-101 hepatocellular carcinoma topline data in Q4 2026 and plans a TTI-109 ulcerative colitis trial in 2027, subject to funding and regulatory clearance.